{"id":1776,"date":"2026-05-28T13:30:02","date_gmt":"2026-05-28T13:30:02","guid":{"rendered":"https:\/\/lotilabs.com\/resources\/?p=1776"},"modified":"2026-05-28T13:30:02","modified_gmt":"2026-05-28T13:30:02","slug":"rad-140-testolone-research-guide-2026-clinical-data-pharmacokinetics-ruo","status":"publish","type":"post","link":"https:\/\/lotilabs.com\/resources\/rad-140-testolone-research-guide-2026-clinical-data-pharmacokinetics-ruo\/","title":{"rendered":"RAD-140 (Testolone) Research Guide: 2026 Clinical Data, Pharmacokinetics & RUO Applications"},"content":{"rendered":"

RAD-140 (Testolone) Research Guide: 2026 Clinical Data, Pharmacokinetics & RUO Applications<\/h1>\n
\"RAD-140<\/figure>\n

RAD-140 (INN: Vosilasarm), commonly known as Testolone, is an investigational non-steroidal Selective Androgen Receptor Modulator (SARM) originally developed by Radius Health. It selectively binds androgen receptors in muscle and bone tissue without converting to estrogen via aromatization or to DHT via 5\u03b1-reduction, achieving anabolic effects without typical steroidal side effects. RAD-140 is strictly not for human consumption<\/strong> and is available for Research Use Only (RUO).<\/p>\n

Chemical identity: PubChem CID 44200882 | IUPAC: 2-chloro-4-[(1R,2S)-1-[5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl]-2-hydroxypropyl]aniline | Molecular formula: C\u2082\u2080H\u2081\u2086ClN\u2085O\u2082 | MW: 393.83 g\/mol | CAS: 1182367-47-0. Developed circa 2010 (Miller CP et al., ACS Med Chem Lett) as a non-steroidal tissue-selective androgen receptor modulator with favorable oral pharmacokinetics and high anabolic-to-androgenic ratio in preclinical models.<\/p>\n

Now advanced by Ellipses Pharmaceuticals under the designation EP0062, Vosilasarm is the subject of active Phase I\/II clinical investigations. Its unique combination of a long 44.7-hour elimination half-life, documented neuroprotective properties via MAPK pathway activation, and ongoing oncology trials (NCT05573126) makes it one of the most scientifically distinct SARMs in the current research landscape.<\/p>\n

At Loti Labs<\/strong>, we recognize that the integrity of independent research depends entirely on the purity and transparency of the compounds used. As a premier provider of research-use-only (RUO) peptides and SARMs, we provide comprehensive analytical data, including COA transparency and ICP-MS testing, to ensure that laboratory models yield accurate, reproducible results. This guide serves as a technical compendium for researchers, detailing the 2026 clinical landscape, updated pharmacokinetic profiles, and the biochemical mechanisms defining RAD-140.<\/p>\n

Disclaimer: RAD-140 (Testolone) is strictly for Research Use Only (RUO). It is not for human consumption, clinical use, or diagnostic purposes. Laboratory safety protocols must be strictly followed when handling this compound.<\/em><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n